ALSO NOTED: Pfizer loses second bid for journal records; Genzyme eyes 170-worker expansion in Ireland;

> A federal judge in Boston denied Pfizer's attempt to get peer reviews and notes from the New England Journal of Medicine; the ruling follows another, similar decision two weeks ago in favor of the Journal of the American Medical Association and the Archives of Internal Medicine. Report

> Genzyme announced plans to expand its manufacturing and research facilities in Waterford, Ireland, planning to hire another 170 people there. Report

> A German patent court revoked Pfizer's protection on Lipitor's active ingredient, but the company says its basic patent on the med remains in force till November 2011. Report

> Wyeth and Progenics Pharmaceutical got Canadian regulators' approval to sell their Relistor drug designed to relieve constipation caused by opiate pain meds. Report

> Rumors of the Lunesta moth's death have been greatly exaggerated: Sepracor intends to use the animated critter in its DTC ads for some time to come. Report

> Bayer denied rumors that it was on the verge of issuing a profit warning. Report

> Older antipsychotics used to pacify nursing home residents may worsen Alzheimer's symptoms, a new study shows. Report

> ProStrakan got clearance to sell its post-operative anti-nausea drug xomolix in Germany, the U.K., and six other countries. Report

> An experimental drug has demonstrated an ability to improve memory and slow the effects of aging in rats. Researchers believe the same drug--S18986--can interact with AMPA in human brains. Report

> The Myelin Repair Foundation has spent $10 million so far to identify 18 new drug leads for multiple sclerosis. Report

> Genzyme is getting some public backing for a $200 million expansion project in the south of Ireland. Report

> Florida lawmakers are looking to cap biotech investment. Report

And Finally... The brouhaha over heparin has cast a spotlight on the use of animal products in therapies. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.